Whitepaper Resources | Natera

Whitepaper

Resources in this stream include all of the Whitepapers.

5 months ago
Seeing beyond the limit: Detect residual disease and assess treatment response

Summary of analytical and clinical data for Signatera™, the first ctDNA assay custom-built for MRD detection and treatment response.

Read Flipbook
5 months ago
Detecting molecular residual disease with Signatera

Design and analytical validation of SignateraTM, the first ctDNA assay custom-built for detecting MRD and assessing treatment response.

Read Flipbook